NCT04770090 (CTC-COL) is a NA clinical trial of Blood samples in Cervical Cancer Stage IA1, sponsored by University Hospital, Montpellier.

Who is sponsoring NCT04770090?

NCT04770090 is sponsored by University Hospital, Montpellier.

What drugs are being tested in NCT04770090?

Interventions in NCT04770090: Blood samples.

What condition does NCT04770090 study?

NCT04770090 studies Cervical Cancer Stage IA1, Cervical Cancer Stage IB1, Cervical Cancer Stage IA2, Cervical Cancer Stage IB2.

Is NCT04770090 still recruiting?

NCT04770090 is currently completed. Last updated 10 July 2025.

Last reviewed 2025-07-10 · How we verify

NCT04770090: CTC-COL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Research of Circulating Tumor Cells Released During Cervical Cancer Surgery

Completed NA Last updated 10 July 2025

What this trial tests

NA trial testing Blood samples in Cervical Cancer Stage IA1 in 200 participants. Completed in 22 August 2022.

Timeline

10 March 2022

Primary endpoint
22 August 2022

22 August 2022

Quick facts

Lead sponsor	University Hospital, Montpellier
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	200
Start date	10 March 2022
Primary completion	22 August 2022
Estimated completion	22 August 2022
Sites	3 locations across France

Drugs / interventions tested

Blood samples — full drug profile →

Conditions studied

Cervical Cancer Stage IA1 — all drugs for Cervical Cancer Stage IA1 →
Cervical Cancer Stage IB1 — all drugs for Cervical Cancer Stage IB1 →
Cervical Cancer Stage IA2 — all drugs for Cervical Cancer Stage IA2 →
Cervical Cancer Stage IB2 — all drugs for Cervical Cancer Stage IB2 →

Sponsor

University Hospital, Montpellier

Who can join

18 and older, female only, with Cervical Cancer Stage IA1 or Cervical Cancer Stage IB1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cervical cancer is a rare pathology. Recent studies showed that the risk of recurrence is higher for patients treated by coelioscopy in comparison with laparotomy. It could be explained by the spread of circulating tumor cells (CTC) due to tumor mobilization during different steps of the surgery. The primary goal is to evaluate the spread of CTC during surgery on peripheral blood samples. The secondary outcome is to evaluation the disease-free survival at 3 and 5 years postoperatively. 20 patients with early stage cervical (IA1 to IB2) eligible to coelioscopic stadification and laparoscopic surgery will be included.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Redefining cancer care: harnessing circulating tumor cells' potential for improved diagnosis and prognosis.
Janjua D, Chaudhary A, Joshi U, Tripathi T, et al · · 2025 · cited 4× · PMID 40676582 · DOI 10.1186/s12935-025-03883-y

Verify or expand the search:

Other trials of Blood samples

Trials testing the same drug.

NCT07460700 — Mesenteric Ischemia Markers Study · NA · recruiting
NCT06996249 — Prospective Data Collection Initiative on Thoracic Malignancies · recruiting
NCT06694363 — New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome · recruiting
NCT06826066 — Involvement of the Immune System in Intrinsic Radiosensitivity · NA · recruiting
NCT06864481 — Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis · recruiting

Other University Hospital, Montpellier trials

Trials by the same sponsor.

NCT07524127 — Phenotyping of Type 2 Inflammation Profile by Rheology of Nasal Secretions and Tissue Quantification of Eosinophilic Pol · NA · not yet recruiting
NCT07255495 — Effects of Neuromuscular Scoliosis Surgery on Nutritional Metabolism · NA · not yet recruiting
NCT07534189 — Prospective Cohort Study Evaluating a Thermal Spa Programme in Symptomatic Knee Osteoarthritis · NA · not yet recruiting
NCT07515638 — Immun4Cure Cohort of Autoimmune Diseases · not yet recruiting
NCT07406516 — Identification of Kinematic Variables Specific of Patellar Tendinopathy in Athletes at Risk · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04770090 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Montpellier
Last refreshed: 10 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04770090.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing